ESPE2015 Poster Category 3 Late Breaking Posters (15 abstracts)
Safety and Efficacy of Long-Acting GH (VRS-317) in Children with GHD: Effects of Dose Change in the Second Treatment Year
George Bright a , Wayne V Moore b , Huong Jil Nguyen c , Gad B Kletter d , Bradley S Miller e , Patricia Y Fechner f , David Ng g , Eric Humphriss a & Jeffrey L Cleland a
aVersartis, Inc., Menlo Park, California, USA; bChildren’s Mercy Hospital and University of Missouri–Kansas City, Kansas City, Missouri, USA; cSierra Medical Research, Clovis, California, USA; dMary Bridge Children’s Hospital, Tacoma, Washington, USA; eUniversity of Minnesota Masonic Children’s Hospital, Minneapolis, Minnesota, USA; fSeattle Children’s Hospital, Seattle, Washington, USA; gResearch Point Global, Inc., Austin, Texas, USA
Background: VRS-317, a novel fusion protein of rhGH exhibiting delayed clearance, serum half-life generally >100 h, and potential for once monthly dosing, was previously evaluated in a 6-month phase 1b/2a study of weekly, twice monthly or monthly dosing (5.0 mg/kg per month) in prepubertal GHD children (n=64).
Objective and hypotheses: We evaluated whether increased VRS-317 dose from 12 to 18 months can offset the decrease in height velocities commonly seen during the 2nd year of daily rhGH treatment.
Method: In an ongoing long-term safety extension study, 63 subjects received an increased dose of VRS-317 (3.5 mg/kg, twice monthly). Peak IGF1 SDS and mean height velocities were compared before and after increased dose.
Results: 56 subjects completed 18 months of treatment. Mean age at Month 18 was 9.28 years; all but two subjects remain prepubertal. Increasing the twice monthly dose from 2.5 to 3.5 mg/kg increased mean peak IGF1 SDS from −0.30±1.2 to 0.32±1.6 (paired t-test, P=0.007); the number of peak IGF1 SDS >2.0 was limited to three values total for all subjects. Increased dosing appeared to stabilize height velocity: during the initial 12 months of treatment, mean height velocity was 7.9±2.1 and 8.5±2.1 cm/year for 5 mg/kg monthly and 2.5 mg/kg twice monthly dosing, respectively, compared with 8.1±2.4 and 8.3±1.8 cm/year (annualized), respectively, after 18 months (3.5 mg/kg twice monthly). Only mild and transient drug-related AEs were observed (n=9 patients after 12 months; n=7 patients after 18 months). No new or unexpected AEs occurred. Injection site discomfort decreased with time on treatment, with only four subjects reporting discomfort after 18 months.
Conclusion: Increasing VRS-317 dose at the start of the 2nd year of treatment to 3.5 mg/kg twice monthly (phase 3 dose) led to in an increase in mean peak IGF1 SDS and stabilization of mean height velocity, without changing the safety profile.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more